InvestorsHub Logo

Bourbon_on_my_cornflakes

04/05/19 2:29 PM

#188325 RE: ClosetInvestor #188324

More tasty ASM tidbits

Good results on p2 for PDD or Alz (p2/3) would produce a big cash deal, IMO. I think Missling is waiting on these trials before signing to maximize $$. Don't think we will have to go alone on p3.

The $1 million was spent to build a stockpile of 273. We have enough for all trials. So no additional cost for product.

BP prefers to pay big $$ when a product is proven through trials, much better to wait until P2 finished.

21 people still taking 273 from the original trial. Their disease has essentially stabliized, ie the graphs they presented on 2 year results are continuing.

Biogen is out of the picture (thank God). dont see any inclination by Dr Missling to bail them out (my interpretation)

PDD becoming a bigger disease due to treatment of P with l-dopa. PDD extensions are at patient requests.

ExtremelyBullishZig

04/05/19 9:50 PM

#188463 RE: ClosetInvestor #188324

Doesn't a 2/3 take place of a phase 3 at some point. Not sure what the point of the "/3" is if that isn't the case.